维普中文期刊产品整合服务
12篇 您的检索式:作者名="KATE MP"
    题名 作者 年代 出处 被引量
1Enhanced benefit fi'om adjuvant chemotherapy in breast cancer patients classified high-risk accoding to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor typel ( N = 3424) 显示文摘Harbeck N Kates RE Look MP Meijer-van Gelder ME Klijn JGM Kruger A 2002Cancer Res2002,2,16:1
2Bilateral perisylvian infarct: a rare cause and a rare occurrence显示文摘Singh A Kate MP Nair MD 2011Singapore Med J2011,52,4:1
3Bilateral perisylvian in- farct: a rare cause and a rare occurrence显示文摘Singh A Kate MP Nair MD 2011Singapore Med J2011,52,4:1
4Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator(uPA)and plasminogen activator inhibitor type 1(n=3424)显示文摘Harbeck N Kates RE Look MP 2002Cancer Res2002,62,16:1
5Hepatitis E in fection with Bell's palsy 显示文摘Dixit VK Abhilash VB Kate MP 2006J Assoc Physicians India2006,54,5:1
6Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424) 显示文摘Harbeck N Kates RE Look MP 2002Cancer Res2002,62,16:1
7Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n=3 424) 显示文摘Harbeck N Kates RE Look MP 2002Cancer Res2002,62,16:1
8Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator and plasminogen activator inhibitor type-1显示文摘Harbeck N Kates RE Look MP 2002Cancer Res2002,62,16:1
9Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to uroki-nase-type plasminogen activator(uPA)and plasminogen activator inhibitor type1(n=3424)显示文摘Harbeck N Kates RE Look MP 2002Cancer Res2002,62,:1
10Prevention of stroke in atrial fibrillation: cautious optimism 显示文摘KATE MP SHUAIB A 2012Lancet Neurology2012,11,3:1
11Trastuzumab:A review of its use in the treatment of metastatic breast cancer overexpresseing HER-2显示文摘Kate MK Caroline MP 2002Drugs2002,62,1:1
12Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n :3424) 显示文摘Harbeek N Kates RE Look MP 2002CancerRes2002,62,16:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费